Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry
The study provides insight into “how far we should go in treating TR . . . and which gradients we should accept,” Andrea Scotti says.
Source: tctmd.com
Trivalve Registry News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Trivalve Registry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Trivalve Registry Today - Breaking & Trending Today
Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances
May 21, 2021 Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR. On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches—annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement—aimed at addressing this clinical niche. All three are manufactured by Edwards Lifesciences: Thirty-day data...
Source: tctmd.com